Mindray(SZ:300760) Da Zhong Ri Bao·2025-07-21 09:21Core Viewpoint - Ever Union, a shareholder of Mindray Medical (300760.SZ), has completed its share reduction plan, selling 5 million shares for over 1 billion yuan, indicating potential concerns about the company's future performance as growth rates decline significantly [1][2][3]. Group 1: Share Reduction Details - Ever Union executed the share reduction plan from July 3 to July 4, 2025, selling 5 million shares at prices ranging from 213.47 yuan to 213.59 yuan per share [1][2]. - The reduction represents approximately 0.41% of the company's total share capital, aligning with the previously disclosed plan [2][3]. Group 2: Company Performance and Challenges - Mindray Medical has encountered a performance ceiling, with projected revenue and net profit growth rates for 2024 dropping to single digits, marking the lowest since its A-share listing [1][3]. - In 2024, the company's revenue growth plummeted to 5.14%, totaling 36.73 billion yuan, while net profit reached 11.67 billion yuan, reflecting a minimal increase of 0.74% year-on-year [3][4]. - The in-vitro diagnostics segment has surpassed the "life information and support" business as the largest revenue source, despite the latter experiencing negative growth [4]. Group 3: Employee Stock Ownership Plan - The company's employee stock ownership plan set a high growth target of 73% for net profit by 2024 compared to 2021, which was not met, resulting in the failure of the third phase of stock unlocking [5][6]. - The actual net profit growth from 2021 to 2024 was insufficient, leading to the management committee reclaiming the shares from the third phase of the plan [5][6]. - In the first quarter of 2025, Mindray Medical's revenue and net profit continued to decline, with a year-on-year decrease of 12.12% and 16.81%, respectively [6].